MediWound (NASDAQ:MDWD) Rating Lowered to Strong Sell at Wall Street Zen

by · The Markets Daily

MediWound (NASDAQ:MDWD – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “strong sell” rating in a report released on Saturday.

Several other analysts have also issued reports on the company. Zacks Research raised MediWound from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 11th. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price objective (up from $31.00) on shares of MediWound in a research report on Friday, November 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of MediWound in a research note on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, MediWound currently has a consensus rating of “Hold” and an average target price of $31.67.

Get Our Latest Analysis on MDWD

MediWound Price Performance

Shares of MediWound stock opened at $17.03 on Friday. The company’s fifty day simple moving average is $17.70 and its 200-day simple moving average is $17.87. The stock has a market capitalization of $218.15 million, a PE ratio of -8.11 and a beta of 0.13. MediWound has a 1-year low of $14.14 and a 1-year high of $22.50.

MediWound (NASDAQ:MDWD – Get Free Report) last posted its quarterly earnings data on Thursday, March 5th. The biopharmaceutical company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.09. MediWound had a negative return on equity of 65.79% and a negative net margin of 140.80%.The firm had revenue of $1.87 million during the quarter, compared to analyst estimates of $2.09 million. As a group, research analysts anticipate that MediWound will post -2.66 EPS for the current year.

Institutional Investors Weigh In On MediWound

Institutional investors have recently bought and sold shares of the business. Rosalind Advisors Inc. raised its holdings in MediWound by 84.0% during the third quarter. Rosalind Advisors Inc. now owns 749,054 shares of the biopharmaceutical company’s stock valued at $13,498,000 after acquiring an additional 341,993 shares during the period. Kotler Kevin bought a new position in shares of MediWound in the fourth quarter worth about $6,225,000. Meitav Investment House Ltd. grew its position in shares of MediWound by 825.7% during the third quarter. Meitav Investment House Ltd. now owns 291,618 shares of the biopharmaceutical company’s stock worth $5,241,000 after purchasing an additional 260,116 shares in the last quarter. Sphera Funds Management LTD. grew its position in shares of MediWound by 24.3% during the fourth quarter. Sphera Funds Management LTD. now owns 230,347 shares of the biopharmaceutical company’s stock worth $4,252,000 after purchasing an additional 45,077 shares in the last quarter. Finally, Silverberg Bernstein Capital Management LLC raised its stake in MediWound by 6.4% during the 4th quarter. Silverberg Bernstein Capital Management LLC now owns 183,924 shares of the biopharmaceutical company’s stock valued at $3,395,000 after purchasing an additional 11,108 shares during the period. Hedge funds and other institutional investors own 46.83% of the company’s stock.

MediWound News Roundup

Here are the key news stories impacting MediWound this week:

  • Positive Sentiment: 2026–2027 revenue guidance raised/outlined above street expectations — the company issued a 2026 revenue target of $24M–$26M (vs. consensus ~$22.6M) and 2027 guidance of $32M–$35M (vs. consensus ~$25.8M), suggesting material top‑line growth ahead if execution stays on track. MediWound outlines $24M–$26M 2026 revenue target while expanding EscharEx clinical programs
  • Positive Sentiment: Clinical and manufacturing progress: EscharEx Phase III (VALUE) is advancing as planned, NexoBrid manufacturing capacity has been expanded and is operational, and management expects regulatory approvals in 2026 — these operational milestones de‑risk near‑term commercialization upside. The company also finished the year with roughly $54M in cash. MediWound Reports Fourth Quarter and Full Year 2025 Financial Results
  • Neutral Sentiment: Company filed its Form 20‑F for fiscal 2025 (routine disclosure). This is standard compliance and provides more detail for investors but is not a catalyst by itself. MediWound Files Annual Report on Form 20-F
  • Neutral Sentiment: Earnings call transcript and details are available for investors who want management color on 2026 assumptions and the EscharEx program; use this to judge credibility of guidance and timing of approvals. MediWound (MDWD) Q4 2025 Earnings Call Transcript
  • Negative Sentiment: Q4 revenue missed expectations — reported quarterly revenue of $1.87M vs. analysts’ ~$2.09M estimate, highlighting a small current revenue base and near‑term sensitivity to sales execution. MediWound (MDWD) Reports Q4 Loss, Lags Revenue Estimates
  • Negative Sentiment: Still unprofitable with wide negative margins — Q4 GAAP loss of $0.56/sh (a smaller loss than expected), but the company reported negative net margin and return on equity, underscoring continued cash burn risk until commercial scale or regulatory approvals materialize. That combination helps explain downward pressure on the stock today. MediWound Reports Fourth Quarter and Full Year 2025 Financial Results

MediWound Company Profile

(Get Free Report)

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.

Further Reading